Connection
Murat Gokden to Carcinoma, Renal Cell
This is a "connection" page, showing publications Murat Gokden has written about Carcinoma, Renal Cell.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.912 |
|
|
|
-
Gokden N, Kemp SA, Gokden M. The utility of Pax-2 as an immunohistochemical marker for renal cell carcinoma in cytopathology. Diagn Cytopathol. 2008 Jul; 36(7):473-7.
Score: 0.292
-
G?kden N, Greene GF, Bayer-Garner IB, Spencer HJ, Sanderson RD, G?kden M. Expression of CD138 (Syndecan-1) in renal cell carcinoma is reduced with increasing nuclear grade. Appl Immunohistochem Mol Morphol. 2006 Jun; 14(2):173-7.
Score: 0.253
-
Gokden N, Mukunyadzi P, James JD, Gokden M. Diagnostic utility of renal cell carcinoma marker in cytopathology. Appl Immunohistochem Mol Morphol. 2003 Jun; 11(2):116-9.
Score: 0.206
-
Sharma SG, Gokden M, McKenney JK, Phan DC, Cox RM, Kelly T, Gokden N. The utility of PAX-2 and renal cell carcinoma marker immunohistochemistry in distinguishing papillary renal cell carcinoma from nonrenal cell neoplasms with papillary features. Appl Immunohistochem Mol Morphol. 2010 Dec; 18(6):494-8.
Score: 0.086
-
Gokden N, Gokden M, Phan DC, McKenney JK. The utility of PAX-2 in distinguishing metastatic clear cell renal cell carcinoma from its morphologic mimics: an immunohistochemical study with comparison to renal cell carcinoma marker. Am J Surg Pathol. 2008 Oct; 32(10):1462-7.
Score: 0.074